氯沙坦钾治疗原发性高血压75例疗效分析(1)
 |
| 第1页 |
参见附件(1989KB，3页)。
[摘要] 目的:评价氯沙坦钾治疗高血压的疗效。方法:将150例符合入组条件的原发性高血压患者随机分为氯沙坦钾治疗组和对照组(卡托普利治疗),每组75例。治疗组服用氯沙坦钾50 mg,1次/d,对照组服用卡托普利25 mg,2次/d,共观察8周。观察各组的治疗效果和不良反应情况。结果:治疗组和对照组患者在治疗前后血压都下降平稳,治疗组和对照组患者血压下降没有明显的差异。对照组和治疗组患者的心率和生化指标没有明显改变,对照组中有2例出现显著的干咳,不能耐受实验,而治疗组没有这种现象。结论:氯沙坦钾治疗原发性高血压安全、有效,其发生不良反应的可能性较卡托普利显著降低。
[关键词] 氯沙坦钾;卡托普利;原发性高血压;疗效;不良反应
[中图分类号] R544.1 [文献标识码]A [文章编号]1674-4721(2010)05(a)-032-03
Effects analysis of losartan on the treatment of primary hypertension in 75 cases
HU Yirong
(Department of Cardiology, Chengdu Western Hospital,Sichuan Province, Chengdu610036, China)
[Abstract] Objective: To observe the effect of losartan on the treatment of hypertension during 8 weeks. Methods: 150 patients with primary hypertension were divided into treatment group and control group. The treatment group was treated with losartan of 50 mg/d for 8 weeks. The others were treated with captopril of 25 mg twice a day for 8 weeks as well. The efficacy and safety were evaluated with clinical, biochemical and blood pressure parameters. Results: Blood pressure was significantly reduced both in treatment group or control group. No difference was observed in the effect of controlling blood pressure in the two groups. No change in heart rate and blood parameters was observed in this study. Hacking cough was observed in control group but not in treatment group. Conclusion: Losartan is an effective and safe drug for the treatment of primary hypertension. In addition, the possibility of occurring side-effects of losartan is much lower than captopril.
[Key words] Losartan; Captopril; Primary hypertension; Treatment effects; Side-effects
高血压是一种严重危害人类健康的慢性疾病,它是最常见的一种心血管疾病。无论是在西方发达国家,还是在中国这样的发展中国家,其发生率都在显著升高。高血压的流行给世界各国都带来了沉重的负担,也严重的危害着全世界人民的健康[1]。血管紧张素转换酶抑制剂(ACEI类)在高血压的治疗中被广泛的应用,其被认为能够良好的控制血压,且可以逆转左室的重构。但是,部分患者不能耐受血管紧张素转换酶抑制剂,会有干咳等并发症,导致治疗依从性下降。氯沙坦钾是非肽类血管紧张素Ⅱ(AngⅡ)受体拮抗剂中第1个上市的药物,本研究旨在评价氯沙坦钾治疗高血压的疗效。
1资料与方法
1.1 一般资料
按照世界卫生组织对于高血压的标准,选择本院门诊或者住院的原发性高血压患者150例,排除继发性高血压、慢性心功能不全、慢性肾功能不全以及合并其他器质性心脏病的患者。此外,对于有脑卒中以及妊娠的患者也予以剔除。所有入组的患者都不伴有严重的靶器官功能的损害,未服用血管紧张素转换酶抑制剂,所有的受试者均为自愿参加本研究,同意停用其他降压药物,签署知情同意书,并保证能够与医生密切合作。对照组和治疗组患者均已经过详细的病史询问、系统体检和心电图检查、心脏X线摄片、超声心动图、Holter以及尿常规、肝功能、肾功能等检查,排除继发性高血压。将这150例符合入组条件的高血压患者随机分为氯沙坦钾治疗组和对照组(卡托普利治疗),每组75例。治疗组中,男性35例,女性40例,平均年龄45岁,高血压的平均病程为3 ......
您现在查看是摘要介绍页，详见PDF附件(1989KB，3页)。